MCID: ANL017
MIFTS: 38

Anal Squamous Cell Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Anal Squamous Cell Carcinoma

MalaCards integrated aliases for Anal Squamous Cell Carcinoma:

Name: Anal Squamous Cell Carcinoma 11 14 16 71
Epidermoid Anal Carcinoma 11
Carcinoma of Anal Margin 71

Classifications:



External Ids:

Disease Ontology 11 DOID:5525
NCIt 49 C9161
SNOMED-CT 68 255084004
UMLS 71 C0349534 C1412036

Summaries for Anal Squamous Cell Carcinoma

Disease Ontology: 11 An anal carcinoma that arises near the squamocolumnar junction.

MalaCards based summary: Anal Squamous Cell Carcinoma, also known as epidermoid anal carcinoma, is related to squamous cell carcinoma and papilloma. An important gene associated with Anal Squamous Cell Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Immune response IL-23 signaling pathway and Malignant pleural mesothelioma. The drugs Nivolumab and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include t cells, cervix and endothelial, and related phenotype is cellular.

Related Diseases for Anal Squamous Cell Carcinoma

Diseases related to Anal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 506)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 30.7 TP53 PIK3CA KRT7 FBXW7 EGFR CDKN2A
2 papilloma 30.6 TP53 KRT7 EGFR CDKN2A
3 suppressor of tumorigenicity 3 30.4 TP53 CDKN2A
4 leiomyosarcoma 30.3 TP53 CDKN2A CD274
5 basaloid squamous cell carcinoma 30.2 TP53 KRT7 CDKN2A
6 lymphatic system disease 30.0 TP53 H2AC18 CD8A CD4
7 malignant peripheral nerve sheath tumor 29.7 TP53 KRT7 EGFR CDKN2A
8 cervical squamous cell carcinoma 29.7 TP53 PIK3CA FBXW7 EGFR CDKN2A
9 rectal benign neoplasm 29.7 TP53 PIK3CA KRT7 EGFR
10 exanthem 29.6 H2AC18 EGFR CD8A CD4 CD274
11 lymphoma, non-hodgkin, familial 29.6 TP53 PIK3CA H2AC18 CD8A CD4 CD274
12 anus cancer 29.5 ZNF582 WDR17 TP53 PIK3CA KRT7 H2AC18
13 basal cell carcinoma 29.5 TP53 KRT7 H2AC18 EGFR CDKN2A
14 human papillomavirus infectious disease 29.4 TP53 PIK3CA EGFR CDKN2A CD8A CD4
15 adenocarcinoma 29.3 TP53 PIK3CA KRT7 EGFR CDKN2A CD274
16 thymoma 29.2 TP53 KRT7 EGFR CDKN2A CD8A CD274
17 head and neck cancer 29.2 TP53 PIK3CA H2AC18 EGFR CDKN2A CD8A
18 adenoid cystic carcinoma 29.1 TP53 PIK3CA KRT7 FBXW7 EGFR CDKN2A
19 vaginal cancer 29.1 TP53 KRT7 EGFR CDKN2A CD8A CD4
20 lymphangioma 29.0 TP53 PIK3CA KRT7 H2AC18 EGFR CD8A
21 endometrial cancer 28.9 TP53 PIK3CA KRT7 H2AC18 FBXW7 EGFR
22 rectum adenocarcinoma 28.8 TP53 PIK3CA KRT7 FBXW7 EGFR CD8A
23 anus disease 28.7 ZNF582 TP53 PIK3CA KRT7 H2AC18 EGFR
24 cervix carcinoma 28.6 TP53 PIK3CA KRT7 H2AC18 EGFR CDKN2A
25 colon squamous cell carcinoma 11.3
26 anal canal carcinoma 10.5
27 anal canal squamous cell carcinoma 10.4
28 neutropenia 10.3
29 rare tumor 10.3
30 autoimmune cardiomyopathy 10.3 CD4 CD274
31 b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) 10.3 TP53 CDKN2A
32 hilar lung neoplasm 10.3 CD8A CD4
33 bizarre leiomyoma 10.3 TP53 CDKN2A
34 cervical basaloid squamous cell carcinoma 10.3 KRT7 CDKN2A
35 diarrhea 10.3
36 anus benign neoplasm 10.3 H2AC18 CDKN2A
37 inverted transitional papilloma 10.3 KRT7 CDKN2A
38 oral tuberculosis 10.3 CD8A CD4
39 early yaws 10.3 CD8A CD4
40 anal canal paget's disease 10.3 KRT7 CDKN2A
41 endometrial transitional cell carcinoma 10.3 KRT7 CDKN2A
42 ventilation pneumonitis 10.3 CD8A CD4
43 atrophic vulva 10.3 KRT7 CDKN2A
44 larynx squamous papilloma 10.3 TP53 CDKN2A
45 diffuse infiltrative lymphocytosis syndrome 10.3 CD8A CD4
46 wissler-fanconi syndrome 10.3 CD8A CD4
47 autoimmune lymphoproliferative syndrome, type iia 10.3 CD8A CD4
48 cervical mucinous adenocarcinoma 10.3 KRT7 CDKN2A
49 vulval paget's disease 10.3 KRT7 CDKN2A
50 encephalitozoonosis 10.3 CD8A CD4

Graphical network of the top 20 diseases related to Anal Squamous Cell Carcinoma:



Diseases related to Anal Squamous Cell Carcinoma

Symptoms & Phenotypes for Anal Squamous Cell Carcinoma

MGI Mouse Phenotypes related to Anal Squamous Cell Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.36 CD274 CD4 CD8A CDKN2A EGFR FBXW7

Drugs & Therapeutics for Anal Squamous Cell Carcinoma

Drugs for Anal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 48)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nivolumab Approved Phase 3 946414-94-4
2
Fluorouracil Approved Phase 3 51-21-8 3385
3
Mitomycin Approved Phase 3 50-07-7 5746
4 Immune Checkpoint Inhibitors Phase 3
5 Immunoglobulins Phase 3
6 Antibodies Phase 3
7
Panitumumab Approved, Investigational Phase 2 339177-26-3
8
Cetuximab Approved Phase 1, Phase 2 205923-56-4
9
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
10
Avelumab Approved, Investigational Phase 1, Phase 2 1537032-82-8
11
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
12
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
13
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
14
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
15
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
16
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
17
Fludarabine Approved Phase 1, Phase 2 75607-67-9, 21679-14-1 30751 657237
18
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
19
Aldesleukin Approved Phase 1, Phase 2 110942-02-4
20 ON 01910 Phase 2
21 Protein Kinase Inhibitors Phase 2
22 Anti-Bacterial Agents Phase 2
23 Alkylating Agents Phase 2
24 Antibiotics, Antitubercular Phase 2
25 Immunosuppressive Agents Phase 2
26 Immunologic Factors Phase 2
27 Vaccines Phase 1, Phase 2
28 Albumin-Bound Paclitaxel Phase 2
29 Antimitotic Agents Phase 2
30 Tubulin Modulators Phase 2
31 Antineoplastic Agents, Immunological Phase 2
32 Antimetabolites Phase 2
33 Immunoglobulins, Intravenous Phase 2
34 Immunoglobulin G Phase 2
35 Angiogenesis Inhibitors Phase 2
36 Antibodies, Monoclonal Phase 2
37 Endothelial Growth Factors Phase 2
38 Mitogens Phase 2
39 Antiviral Agents Phase 1, Phase 2
40 Anti-Retroviral Agents Phase 1, Phase 2
41 Anti-Infective Agents Phase 1, Phase 2
42 Anti-HIV Agents Phase 1, Phase 2
43 Antirheumatic Agents Phase 1
44 Antineoplastic Agents, Alkylating Phase 1
45 Interleukin-2 Phase 1
46 Analgesics, Non-Narcotic Phase 1
47 Analgesics Phase 1
48 Cola

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Na�ve Metastatic Anal Cancer Patients Recruiting NCT04444921 Phase 3 Carboplatin;Paclitaxel
2 A Phase 3, Multicenter, Double-Blind Randomized Study of Mitomycin, 5-Fluorouracil and IMRT Combined With or Without Anti-PD-1 in Patients With Locally Advanced Anal Canal Squamous Carcinoma Recruiting NCT05374252 Phase 3 PD-1 inhibitor
3 Phase 2 Trial to Assess the Efficacy and Safety of Chemoradiation With 5-fluorouracil, Mytomicin C and Panitumumab as a Treatment for Anal Squamous Cell Carcinoma Completed NCT01285778 Phase 2 panitumumab, mytomicin C, 5-FU, radiation
4 A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma Completed NCT01807546 Phase 2 rigosertib
5 A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) Recruiting NCT04166318 Phase 2 Capecitabine;Fluorouracil;Mitomycin
6 A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 Monotherapy or in Combination With Cetuximab as a Salvage Regimen for Solid Tumors Recruiting NCT04616196 Phase 1, Phase 2 NKTR-255;Cetuximab
7 Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients Recruiting NCT05060471 Phase 2 Toripalimab
8 A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons Recruiting NCT02437851 Phase 2
9 A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies. Recruiting NCT03260023 Phase 1, Phase 2 Avelumab
10 Risk-Adapted Therapy for HIV-Associated Anal Cancer Recruiting NCT04929028 Phase 2 Capecitabine;Fluorouracil;Mitomycin
11 ROAR-A: Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer Recruiting NCT05438836 Phase 2
12 InterAACT - An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5-Fluorouracil Versus Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease Active, not recruiting NCT02560298 Phase 2 Capecitabine;Carboplatin;Cisplatin;Fluorouracil;Paclitaxel
13 A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and Bevacizumab in Rare Solid Tumors Active, not recruiting NCT03074513 Phase 2 Atezolizumab
14 A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers Not yet recruiting NCT05639972 Phase 1, Phase 2 Conditioning, E7 TCR-T cells, and aldesleukin
15 An Open-label, Phase II, Multi-cohort, 2-stage Trial to Evaluate the Efficacy and Safety of Regorafenib in Combination With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Pretreated Solid Cancers Not yet recruiting NCT05582031 Phase 2
16 A Phase 1 Study of LY2606368 in Patients With Advanced Cancer Completed NCT01115790 Phase 1 Prexasertib
17 A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors Terminated NCT04596033 Phase 1 IL-2;Fludarabine;Cyclophosphamide
18 Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy Completed NCT02145416
19 Proton Versus Photon Therapy in Anal Squamous Cell Carcinoma - Swedish Anal Carcinoma Study Recruiting NCT04462042
20 Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer. Recruiting NCT03061435
21 Circulating HPV DNA in Cancers of the Anus and Uterine Cervix Treated With Definitive Radiation Therapy Recruiting NCT04857528
22 The Role of a 4-point Therapy Response Score With PET/CT Post Definitive Chemoradiation for Anal Squamous Cell Cancer: A Prospective Study Recruiting NCT05130073
23 ACTION HIV (Anal Cancer TherapIes and Outcomes iNitiative for Patients Living With and Without HIV): A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection Not yet recruiting NCT05328765
24 Prospective Validation Study Under CLIA-compliant SOPs for the Proprietary Rectal and Anal Cancer Protein Expression Assays Terminated NCT02407561

Search NIH Clinical Center for Anal Squamous Cell Carcinoma

Genetic Tests for Anal Squamous Cell Carcinoma

Anatomical Context for Anal Squamous Cell Carcinoma

Organs/tissues related to Anal Squamous Cell Carcinoma:

MalaCards : T Cells, Cervix, Endothelial, Lymph Node, Myeloid, Liver, Bone Marrow

Publications for Anal Squamous Cell Carcinoma

Articles related to Anal Squamous Cell Carcinoma:

(show top 50) (show all 542)
# Title Authors PMID Year
1
Failure of Initial Curative Treatment for Non-Metastatic Anal Squamous Cell Carcinoma: From Prognostic Factors Analysis to Stratified Treatment. 62
35934635 2022
2
Impact of Time From Diagnosis to Treatment Start on the Outcomes of Patients With Nonmetastatic Anal Squamous Cell Carcinoma. 62
36453694 2022
3
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation. 62
36409453 2022
4
Demographics and incidence of anal squamous cell carcinoma in people living in high HIV prevalence geographical areas. 62
34887349 2022
5
The first comprehensive genomic characterization of rectal squamous cell carcinoma. 62
36357817 2022
6
Characteristics and oncological results of epidermoid anal carcinoma: Comparison analysis between immunocompetent and immunosuppressed patients. 62
35850478 2022
7
Successful Management of Anal Squamous Cell Carcinoma With Liver and Ovary Metastases: A Case Report. 62
36309369 2022
8
Influence of radiation treatment technique (IMRT vs. 3D-RT) on acute toxicity and prognostic factors for survival for anal cancer. 62
36402828 2022
9
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer. 62
36455685 2022
10
Artificial intelligence and high-resolution anoscopy: automatic identification of anal squamous cell carcinoma precursors using a convolutional neural network. 62
35986806 2022
11
Concurrent Chemo-radiotherapy in Anal Squamous Cell Carcinoma: A Retrospective Review of a Tertiary Centre Experience. 62
36269537 2022
12
A nationwide longitudinal study on risk factors for progression of anal intraepithelial neoplasia grade 3 to anal cancer. 62
35657350 2022
13
The effect of human immunodeficiency virus and human papillomavirus strain diversity on the progression of anal squamous intraepithelial lesions. 62
35803414 2022
14
Role of local therapy in the management of patients with metastatic anal squamous cell carcinoma: a National Cancer Database study. 62
36388688 2022
15
Colorectal Surgery Practice, Training, and Research in Low-Resource Settings. 62
36111082 2022
16
Management of anal squamous cell carcinoma and its recurrences. 62
35599084 2022
17
Author's reply: "Management of anal squamous cell carcinoma and its recurrences". 62
35811231 2022
18
Pretreatment colostomy in patients with anal squamous cell carcinoma: Risk factors for a permanent stoma. 62
35639271 2022
19
Impact of HIV on Anal Squamous Cell Carcinoma Rates in the United States, 2001-2015. 62
35575389 2022
20
Our experience in the short-term diagnostic-therapeutic management of the patient with anal dysplasia. 62
36152962 2022
21
Programmed Death Ligand-1 Expression Is Associated With Poorer Survival in Anal Squamous Cell Carcinoma. 62
34936703 2022
22
Trends in utilization of first-line palliative treatments for anal squamous cell carcinoma. 62
36082966 2022
23
Development and validation of prognostic models for anal cancer outcomes using distributed learning: protocol for the international multi-centre atomCAT2 study. 62
35922837 2022
24
Anal squamous cell carcinoma in HIV patients with HPV-16 condylomas: a serious complication in immunocompromised patients. 62
35297261 2022
25
Combined PET-CT and MRI for response evaluation in patients with squamous cell anal carcinoma treated with curative-intent chemoradiotherapy. 62
35274187 2022
26
The Prognostic Role of Baseline Eosinophils in HPV-Related Cancers: a Multi-institutional Analysis of Anal SCC and OPC Patients Treated with Radical CT-RT. 62
35915202 2022
27
Robotic beyond total mesorectal excision surgery for primary and recurrent pelvic malignancy: Feasibility and short-term outcomes. 62
35373888 2022
28
Anal intraepithelial neoplasia: a review of terminology, differential diagnoses, and patient management. 62
35843339 2022
29
Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab: A case report. 62
36051149 2022
30
Anal cytology screening in men who have sex with men with HIV at a university hospital in Bogotá, Colombia. 62
35491739 2022
31
Long-term Patterns of Failure and the Value of Blood Prognostic Markers in Anal Cancers Treated With Intensity-Modulated Radiation Therapy. 62
34799240 2022
32
Short-term effectiveness and tolerability of carbon dioxide laser for anal high-grade squamous intraepithelial lesions in individuals living with HIV. 62
35611790 2022
33
Leukocyte subtyping predicts for treatment failure and poor survival in anal squamous cell carcinoma. 62
35751111 2022
34
Metastatic Anal Squamous Cell Carcinoma Presenting as an Indeterminate Biliary Stricture Diagnosed By Cholangioscopy. 62
35765678 2022
35
Stage IV anal canal squamous cell carcinoma with long-term survival: a case report. 62
35723765 2022
36
Detection of Anal Intraepithelial Neoplasia and Anal Squamous Cell Carcinoma on Colonoscopy. 62
35756724 2022
37
Anorectal pathology in the HIV population: a guide for radiologists. 62
35284963 2022
38
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. 62
35114169 2022
39
Increased risk of genital warts in inflammatory bowel disease: A Danish registry-based cohort study (1996-2018). 62
35297191 2022
40
Anal squamous cell carcinoma: a retrospective case series. 62
33977391 2022
41
Treatment strategy for vertebral metastases from anal squamous cell carcinoma: a comprehensive literature review and case report. 62
35369848 2022
42
Perineal Reconstruction With the Profunda Artery Perforator Flap. 62
34510081 2022
43
The influence of HIV status on the duration of chemoradiotherapy for anal squamous cell carcinoma. 62
35451264 2022
44
Prognostic Value of Fusobacterium nucleatum after Abdominoperineal Resection for Anal Squamous Cell Carcinoma. 62
35406380 2022
45
Mitomycin-Induced Thrombotic Thrombocytopenic Purpura Treated Successfully With Plasmapheresis and Steroid: A Case Report. 62
35494991 2022
46
Carcinogenesis and Cancer Progression in De Novo Anal Squamous Cell Carcinoma After Organ Transplantation: A Systematic Review. 62
35282809 2022
47
Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG). 62
34999135 2022
48
Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. 62
35305097 2022
49
New approaches in palliative systemic therapy of anal squamous cell carcinoma. 62
35760571 2022
50
Hepatic metastasis of anal squamous cell carcinoma. 62
35039378 2022

Variations for Anal Squamous Cell Carcinoma

Expression for Anal Squamous Cell Carcinoma

Search GEO for disease gene expression data for Anal Squamous Cell Carcinoma.

Pathways for Anal Squamous Cell Carcinoma

Pathways related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.31 TP53 PIK3CA EGFR CD4
2 12.27 TP53 PIK3CA EGFR CDKN2A CD274
3
Show member pathways
12.09 PIK3CA CD8A CD4 CD274
4 11.68 PIK3CA EGFR CDKN2A
5 11.34 TP53 PIK3CA FBXW7
6
Show member pathways
11.2 TP53 PIK3CA CDKN2A CD8A CD4
7 11.12 TP53 PIK3CA EGFR CDKN2A
8 10.93 TP53 EGFR CDKN2A
9 10.43 PIK3CA EGFR
10 10.1 TP53 PLK3

GO Terms for Anal Squamous Cell Carcinoma

Biological processes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of miRNA maturation GO:1903800 8.62 TP53 EGFR

Sources for Anal Squamous Cell Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....